TIM
RCUS icon

Tortoise Investment Management’s Arcus Biosciences RCUS Stock Holding History

Tortoise Investment Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3
Closed -$41 – 1162
2025
Q3 		$41 Buy
+3
New +$31 ﹤0.01% 1518

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Tortoise Investment Management's RCUS Position: Q4 2025 in Review

Tortoise Investment Management sold out of Arcus Biosciences (RCUS) in Q4 2025, closing a stake of 3 shares — an estimated $41 sold.

Tortoise Investment Management first reported a position in RCUS in Q3 2025 and held it in 1 quarter. The position peaked at $41 in Q3 2025. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.

  • Tortoise Investment Management reported no remaining Arcus Biosciences position as of Q4 2025 after selling out during the quarter.
  • Tortoise Investment Management sold 3 Arcus Biosciences shares in Q4 2025, an estimated $41.
  • Tortoise Investment Management first reported a position in Arcus Biosciences in Q3 2025 and held it in 1 quarter.
  • Tortoise Investment Management's Arcus Biosciences position peaked at $41 in Q3 2025.
  • 209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.

Based on Tortoise Investment Management's 13F filing for Q4 2025, filed 6 Feb 2026.